Celgene Corp (CELG) 93.85 $CELG
Midday Glance: Biotechnology companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Nasdaq Touches 52-Week High; Concur Soars On Buyout
at Investor's Business Daily - Fri Sep 19, 10:50AM CDT
Stocks added to recent gains Friday as the Dow Jones industrial average and S&P 500 moved further into all-time high territory. The Nasdaq touched a 52-week high. About two hours into the session, the Dow added 0.3%; the S&P 500 added 0.2% and the...
Celgene (CELG) Is Today's Momo Momentum Stock
at The Street - Fri Sep 19, 9:44AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
Early Glance: Biotechnology companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
Celgene Appoints Tuomo Patsi as President of EMEA and Commits to Continue Delivering Innovative Solutions to Meet Patient Needs Across the Region
Business Wire - Fri Sep 19, 7:02AM CDT
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that Tuomo Patsi has been appointed President of the Europe, Middle East and Africa (EMEA) region for the company. In this role, he will oversee the current portfolio in EMEA as well as international efforts related to the company's broad pipeline of clinical programs in areas including immunotherapy, epigenetics, ubiquitin ligase targets, cancer metabolism and others. Mr. Patsi takes over from Alan Colowick, MD, who has led Celgene in the region since 2012 and who returns to the United States, taking on another senior strategic position for the company.
Final Glance: Biotechnology companies
AP - Thu Sep 18, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
3 Best Stocks for Investing in Biotech
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 18, 7:35AM CDT
Few baskets are as hit-and-miss as biotech. The group is notoriously fickle and maddeningly volatile -- and for good reason. Whims and whispers tied to the latest clinical trial results can move biotech stocks in fits and starts, making them best...
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
Safety Worries Over Celgene's Experimental Crohn's Drug Overblown
at The Street - Wed Sep 17, 7:26AM CDT
The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.
Celgene (CELG) Crosses Pivot Point Resistance at $90.93
Comtex SmarTrend(R) - Tue Sep 16, 10:14AM CDT
Shares of Celgene (NASDAQ:CELG) have bullishly opened above the pivot of $89.58 today and have reached the first resistance level of $90.93. Investors may be interested in a cross of the next upside pivot targets of $92.41 and $95.24.
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Jim Cramer's 'Mad Money' Recap: Time to Make Room for Alibaba
at The Street - Mon Sep 15, 7:00PM CDT
The market is getting weird and the fast-growing, high-multiple stocks are getting clobbered, Cramer says.
Midday Glance: Biotechnology companies
AP - Fri Sep 19, 12:33PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Nasdaq Touches 52-Week High; Concur Soars On Buyout
at Investor's Business Daily - Fri Sep 19, 10:50AM CDT
Stocks added to recent gains Friday as the Dow Jones industrial average and S&P 500 moved further into all-time high territory. The Nasdaq touched a 52-week high. About two hours into the session, the Dow added 0.3%; the S&P 500 added 0.2% and the...
Celgene (CELG) Is Today's Momo Momentum Stock
at The Street - Fri Sep 19, 9:44AM CDT
Trade-Ideas LLC identified Celgene (CELG) as a momo momentum candidate
Early Glance: Biotechnology companies
AP - Fri Sep 19, 9:16AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent
PR Newswire - Fri Sep 19, 7:15AM CDT
BioTech News Coverage: Progress made as biotech companies release latest developments, patents and results of studies and trials. Companies in focus are: GenSpera Inc. (OTC: GNSZ), Eli Lilly and Company (NYSE: LLY), Gilead Sciences Inc. (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA)
Celgene Appoints Tuomo Patsi as President of EMEA and Commits to Continue Delivering Innovative Solutions to Meet Patient Needs Across the Region
Business Wire - Fri Sep 19, 7:02AM CDT
Celgene International Sarl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that Tuomo Patsi has been appointed President of the Europe, Middle East and Africa (EMEA) region for the company. In this role, he will oversee the current portfolio in EMEA as well as international efforts related to the company's broad pipeline of clinical programs in areas including immunotherapy, epigenetics, ubiquitin ligase targets, cancer metabolism and others. Mr. Patsi takes over from Alan Colowick, MD, who has led Celgene in the region since 2012 and who returns to the United States, taking on another senior strategic position for the company.
Final Glance: Biotechnology companies
AP - Thu Sep 18, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
3 Best Stocks for Investing in Biotech
Todd Campbell, The Motley Fool - Motley Fool - Thu Sep 18, 7:35AM CDT
Few baskets are as hit-and-miss as biotech. The group is notoriously fickle and maddeningly volatile -- and for good reason. Whims and whispers tied to the latest clinical trial results can move biotech stocks in fits and starts, making them best...
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
Safety Worries Over Celgene's Experimental Crohn's Drug Overblown
at The Street - Wed Sep 17, 7:26AM CDT
The first public presentation of the GED-031 phase II data will be on Oct. 21 at a European medical conference.
Jim Cramer's 'Mad Money' Recap: Let's Hear It for the Bull
at The Street - Tue Sep 16, 7:20PM CDT
The markets can continue to rebound but only if a few other things go right, Cramer says.
Celgene (CELG) Crosses Pivot Point Resistance at $90.93
Comtex SmarTrend(R) - Tue Sep 16, 10:14AM CDT
Shares of Celgene (NASDAQ:CELG) have bullishly opened above the pivot of $89.58 today and have reached the first resistance level of $90.93. Investors may be interested in a cross of the next upside pivot targets of $92.41 and $95.24.
Stock Market News for September 16, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 9:10AM CDT
Benchmarks settled mostly in the red zone on Monday, dragged down by declines in technology and small-cap stocks
Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
PR Newswire - Tue Sep 16, 8:00AM CDT
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
Jim Cramer's 'Mad Money' Recap: Time to Make Room for Alibaba
at The Street - Mon Sep 15, 7:00PM CDT
The market is getting weird and the fast-growing, high-multiple stocks are getting clobbered, Cramer says.
